Research & Development
Sobi's Tryngolza for severe hypertriglyceridaemia receives EU approval
17 November 2026 -

Swedish biopharmaceutical company Sobi (STO: SOBI), which focuses on rare diseases, said on Tuesday that the European Commission has approved Tryngolza (olezarsen) for adults with severe hypertriglyceridaemia (sHTG).

It is the first and only RNA-targeted therapy authorised in the EU for this group.

The decision follows an early positive opinion from the Committee for Medicinal Products for Human Use in October, and widens the existing marketing authorisation for Tryngolza, which already covers familial chylomicronaemia syndrome.

Approval rests on the Phase 3 CORE and CORE2 studies. In patients with baseline triglyceride levels of at least 880 mg/dL, Tryngolza cut triglycerides by up to 73% at six months versus placebo (p

Login
Username:

Password: